Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (BRIO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03370185
Recruitment Status : Withdrawn (Reassessing corporate priorities.)
First Posted : December 12, 2017
Last Update Posted : March 17, 2021
Information provided by (Responsible Party):

Brief Summary:
This is a multi-center, single-arm, open-label, Phase 2 study of duvelisib, an orally bioavailable dual inhibitor of PI3K-δ,γ, in patients with CLL/SLL who have previously been treated with ibrutinib or another Bruton's Tyrosine Kinase Inhibitor (BTKi) and relapsed or were refractory to such therapy or discontinued such therapy due to toxicity.

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Drug: Duvelisib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Duvelisib Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi)
Actual Study Start Date : February 12, 2018
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : March 2021

Arm Intervention/treatment
Experimental: Duvelisib
Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
Drug: Duvelisib
Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles

Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: From start of treatment to first documented response, 2 cycles (58 days) ]

Secondary Outcome Measures :
  1. Treatment-Emergent adverse events (TEAEs) and changes in laboratory values [ Time Frame: From start of treatment to end of treatment plus 30 days; 7 months ]
  2. Duration of response (DOR), defined as the time from the first documentation of response to the first documentation of PD or death due to any cause [ Time Frame: Time from the first documentation of response to first documentation of progressive disease or death due to any cause, 6 months ]
  3. Progression-free survival (PFS), defined as the time from the first dose of study treatment to the first documentation of PD or death from any cause [ Time Frame: Time from start of treatment to first documentation of progression or date of death from any cause, whichever came first, 4 months ]
  4. Disease control rate (DCR), defined as CR/CRi + PR/PRwL + stable disease (SD) ≥ 8 weeks [ Time Frame: Greater than or equal to 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. ≥ 18 years of age.
  2. Diagnosis of CLL or SLL.
  3. Received at least one prior anti-cancer therapy for CLL or SLL.
  4. Previous exposure to BTKi and meet at least one of the criteria below:

    1. Progressive disease (PD) while receiving or within 6 months after completing BTKi therapy.
    2. Discontinued a BTKi therapy due to BTKi treatment- related intolerance.
  5. Measurable disease with a lymph node or tumor mass > 1.5 cm in at least one dimension.
  6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  7. Resolution of toxicities due to prior BTKi therapy to acceptable level.
  8. Willingness of male and female patients to use medically acceptable methods of birth control.
  9. Willing and able to participate in all required study evaluations and procedures.

Exclusion Criteria:

  1. Richter's transformation or prolymphocytic leukemia
  2. Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
  3. Received prior transplant
  4. Experienced PD or serious adverse events on a prior phosphoinositide-3-kinase (PI3K) inhibitor
  5. Known central nervous system involvement by CLL/SLL

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03370185

Layout table for location information
United States, Arizona
Arizona Oncology
Tempe, Arizona, United States, 85284
United States, Arkansas
Genesis Cancer Center
Hot Springs, Arkansas, United States, 71913
United States, California
Moores UC San Diego Cancer Center
La Jolla, California, United States, 92093
United States, Illinois
Ingalls Memorial Hospital
Harvey, Illinois, United States, 60426
United States, Michigan
QUEST Research Institute
Royal Oak, Michigan, United States, 48073
United States, Montana
St. Vincent Frontier Cancer Center
Billings, Montana, United States, 59102
United States, New Jersey
Summit Medical Group
Morristown, New Jersey, United States, 07932
United States, Washington
Medical Oncology Associates PS, WA
Spokane, Washington, United States, 99208
Sponsors and Collaborators
Layout table for investigator information
Study Director: David Cohan, MD SecuraBio Chief Medical Officer
Layout table for additonal information
Responsible Party: SecuraBio Identifier: NCT03370185    
Other Study ID Numbers: VS-0145-224
First Posted: December 12, 2017    Key Record Dates
Last Update Posted: March 17, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by SecuraBio:
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell